Managing challenging patients with venous thromboembolism: A practical, case-based approach

Polish Archives of Internal Medicine

Volumn 127, Issue 1, 2017, Pages 41-46

  Douketis, James ^a   Ageno, Walter ^b   Carrier, Marc ^c   Kearon, Clive ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Anticoagulant therapy; Cancer associated thrombosis; Deep vein thrombosis; Pulmonary embolism; Thrombolytic therapy

Indexed keywords

DALTEPARIN; ENOXAPARIN; TINZAPARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; BLOOD CLOT LYSIS; BRAIN METASTASIS; CLINICAL DECISION MAKING; DISEASE ASSOCIATION; HUMAN; LEG SWELLING; OUTCOME ASSESSMENT; PHLEBOGRAPHY; REVIEW; RISK ASSESSMENT; SMALL CELL LUNG CANCER; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; ADULT; AGED; CASE REPORT; COMPLICATION; DISEASE MANAGEMENT; EVIDENCE BASED MEDICINE; FEMALE; MALE; MIDDLE AGED; PRACTICE GUIDELINE; ANTICOAGULANT THERAPY; BALLOON DILATATION; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DISABILITIES OF THE ARM, SHOULDER AND HAND (SCORE); FIBRINOLYTIC THERAPY; GASTROINTESTINAL ENDOSCOPY; INTERNATIONAL NORMALIZED RATIO; PROPHYLAXIS; RECURRENCE RISK;

ADULT; AGED; ANTICOAGULANTS; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; VENOUS THROMBOEMBOLISM;

EID: 85014126987     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.3879     Document Type: Review

References (46)

1. Douketis JD. The 2016 American College of Chest Physicians treatment guidelines for venous thromboembolism: a review and critical appraisal. Intern Emerg Med. 2016;11:1031-1035.
2. Di Nisio M, Van Es N, Buller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016.
3. Kearon C. Diagnosis of suspected venous thromboembolism. Hematology Am Soc Hematol Educ Program. 2016;2016:397-403.
4. Di Nisio M, Ageno W, Rutjes AW, et al. Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Thromb Haemost. 2016;115:424-432.
5. Dentali F, Di Minno MN, Gianni M, et al. Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature. Intern Emerg Med. 2015;10:507-514.
6. Castellucci LA, Cameron C, Le Gal G, et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA. 2014;312:1122-1135.
7. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149:315-352.
8. Van Es N, Di Nisio M, Bleker SM, et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost. 2015;114:1268-1276.
9. Vedantham S, Goldhaber SZ, Kahn SR, et al. Rationale and design of the ATTRACT Study: a multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention of postthrombotic syndrome in patients with proximal deep vein thrombosis. Am Heart J. 2013;165:523-530.
10. Spencer FA, Gore JM, Reed G, et al. Venous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study. Thromb Haemost. 2009;101:878-885.
11. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1, 626 patients. Haematologica. 2007;92:199-205.
12. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ. 2011;342:d3036.
13. Carrier M, Lazo-Langner A, Shivakumar S, et al. Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med. 2015;373:697-704.
14. Douketis J, Tosetto A, Marcucci M, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010;153:523-531.
15. Stevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016;41:154-164.
16. Kearon C, Spencer FA, O'Keeffe D, et al. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med. 2015;162:27-34.
17. Rodger MA, Scarvelis D, Kahn SR, et al. Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort. Thromb Res. 2016;143:152-158.
18. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152:578-589.
19. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003;139:893-900.
20. Van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124:1968-1975.
21. Douketis JD, Arneklev K, Goldhaber SZ, et al. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med. 2006;166:853-859.
22. Palareti G, Cosmi B, Legnani C, et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood. 2014;124:196-203.
23. Douketis JD, Kearon C, Bates S, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279:458-462.
24. Douketis JD, Gu CS, Schulman S, et al. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med. 2007;147:766-774.
25. Ensor J, Riley RD, Moore D, et al. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open. 2016;6:e011 190.
26. Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179:417-426.
27. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121:1630-1636.
28. Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10:1019-1025.
29. Kearon C, Iorio A, Palareti G; Subcommittee on Control of Anticoagulation of the SSCotI. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost. 2010;8:2313-2315.
30. Rodger M, Carrier M, Gandara E, Le Gal G. Unprovoked venous thromboembolism: Short term or indefinite anticoagulation? Balancing long-term risk and benefit. Blood Rev. 2010;24:171-178.
31. Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood. 2014;123:1794-1801.
32. Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost. 2010;8:2436-2442.
33. Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959-1967.
34. Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367:1979-1987.
35. Akl EA, Kahale L, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014: CD006650.
36. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.
37. Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41:81-91.
38. Riva N, Ageno W, Poli D, et al. Recurrent thrombotic events after discontinuation of vitamin k antagonist treatment for splanchnic vein thrombosis: a multicenter retrospective cohort study. Gastroenterol Res Pract. 2015;2015:620 217.
39. Riva N, Ageno W, Schulman S, et al. Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. Lancet Haematol. 2016;3:e267-e275.
40. Liew A, Douketis J. Catheter-directed thrombolysis for extensive iliofemoral deep vein thrombosis: review of literature and ongoing trials. Expert Rev Cardiovasc Ther. 2016;14:189-200.
41. Vedantham S, Kahn SR, Goldhaber SZ, et al. Endovascular therapy for advanced post-thrombotic syndrome: Proceedings from a multidisciplinary consensus panel. Vasc Med. 2016;21:400-407.
42. Haig Y, Enden T, Grøtta O, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT):5-year followup results of an open-label, randomised controlled trial. Lancet Haematol. 2016;3:e64-e71.
43. Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet. 2014;383:880-888.
44. Kahn SR, Galanaud J P, Vedantham S, Ginsberg JS. Guidance for the prevention and treatment of the post-thrombotic syndrome. J Thromb Thrombolysis. 2016;41:144-153.
45. Righini M, Galanaud J P, Guenneguez H, et al. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. Lancet Haematol. 2016;3:e556-e562.
46. Wendelboe AM, McCumber M, Hylek EM, et al. Global public awareness of venous thromboembolism. J Thromb Haemost. 2015;13:1365-1371.